TGFB1 and cancer: miR-382 also target superoxide dismutase 2 (SOD2) to mediate TGF-β1-induced epithelial-mesenchymal transition (EMT) (41), which results in the acquisition of cell invasion and drug resistance, and reversion to cancer stem cells (42).